On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025

Second Antibody Drug Conjugate Is Next Milestone

AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.

Astrazeneca
New oncology drugs are expected to fuel growth to 2030 and beyond. • Source: Shutterstock

Pascal Soriot has set his sights on AstraZeneca leading the industry in terms of growth within the decade, encouraged by strong performances from key products in the second quarter. AstraZeneca's revenues were up by 31% (37% CER) in Q2 to $10.77bn, lifted by better-than-expected sales of its leading cancer and cardiovascular therapies and the COVID-19 drug Evusheld.

Its growth rate was flattered by the addition of revenues from its rare disease unit Alexion, but even so AstraZeneca...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip